$4.64
-0.42[-8.30%]
At close: Apr 18
$4.64
0[0.00%]
After Hours: 4:01PM EDT
2seventy bio
(NASDAQ:TSVT)2seventy bio Stock (NASDAQ:TSVT), Analyst Ratings, Price Targets, Predictions
2seventy bio Inc has a consensus price target of $9.67, established from looking at the 32 latest analyst ratings. The last 3 analyst ratings were released from Citigroup, Wedbush, and Leerink Partners on April 8, 2024, March 18, 2024, and January 31, 2024. With an average price target of $11.67 between Citigroup, Wedbush, and Leerink Partners, there's an implied 151.44% upside for 2seventy bio Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Citigroup
Wedbush
Leerink Partners
TD Cowen
Guggenheim
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for 2seventy bio
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/08/2024 | TSVT | Buy Now | 2seventy bio | $4.64 | 158.62% | Citigroup | Samantha Semenkow | $9 → $12 | Maintains | Buy | Get Alert |
| 03/18/2024 | TSVT | Buy Now | 2seventy bio | $4.64 | 7.76% | Wedbush | David Nierengarten | → $5 | Reiterates | Neutral → Neutral | Get Alert |
| 01/31/2024 | TSVT | Buy Now | 2seventy bio | $4.64 | 287.93% | Leerink Partners | Daina Graybosch | $5 → $18 | Upgrade | Market Perform → Outperform | Get Alert |
| 01/31/2024 | TSVT | Buy Now | 2seventy bio | $4.64 | — | TD Cowen | Yaron Werber | — | Downgrade | Outperform → Market Perform | Get Alert |
| 11/20/2023 | TSVT | Buy Now | 2seventy bio | $4.64 | -56.9% | Wedbush | David Nierengarten | → $2 | Downgrade | Outperform → Neutral | Get Alert |
| 10/30/2023 | TSVT | Buy Now | 2seventy bio | $4.64 | — | Leerink Partners | Daina Graybosch | — | Downgrade | Outperform → Market Perform | Get Alert |
| 10/12/2023 | TSVT | Buy Now | 2seventy bio | $4.64 | 180.17% | Citigroup | Samantha Semenkow | → $13 | Initiates | → Buy | Get Alert |
| 09/13/2023 | TSVT | Buy Now | 2seventy bio | $4.64 | — | Guggenheim | Kelsey Goodwin | — | Downgrade | Buy → Neutral | Get Alert |
| 09/13/2023 | TSVT | Buy Now | 2seventy bio | $4.64 | 7.76% | Goldman Sachs | Salveen Richter | → $5 | Downgrade | Buy → Neutral | Get Alert |
| 09/12/2023 | TSVT | Buy Now | 2seventy bio | $4.64 | — | Guggenheim | Kelsey Goodwin | — | Downgrade | Buy → Neutral | Get Alert |
| 08/15/2023 | TSVT | Buy Now | 2seventy bio | $4.64 | 460.34% | Guggenheim | Kelsey Goodwin | $27 → $26 | Maintains | Buy | Get Alert |
| 08/15/2023 | TSVT | Buy Now | 2seventy bio | $4.64 | 417.24% | Goldman Sachs | Salveen Richter | $27 → $24 | Maintains | Buy | Get Alert |
| 07/28/2023 | TSVT | Buy Now | 2seventy bio | $4.64 | 374.14% | Wedbush | David Nierengarten | $26 → $22 | Maintains | Outperform | Get Alert |
| 07/28/2023 | TSVT | Buy Now | 2seventy bio | $4.64 | 180.17% | Morgan Stanley | Matthew Harrison | $25 → $13 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 07/20/2023 | TSVT | Buy Now | 2seventy bio | $4.64 | 438.79% | Morgan Stanley | Matthew Harrison | $28 → $25 | Maintains | Overweight | Get Alert |
| 05/18/2023 | TSVT | Buy Now | 2seventy bio | $4.64 | 460.34% | Wedbush | David Nierengarten | → $26 | Reiterates | Outperform → Outperform | Get Alert |
| 05/15/2023 | TSVT | Buy Now | 2seventy bio | $4.64 | 460.34% | Wedbush | David Nierengarten | → $26 | Reiterates | Outperform → Outperform | Get Alert |
| 03/17/2023 | TSVT | Buy Now | 2seventy bio | $4.64 | 352.59% | Wedbush | David Nierengarten | $28 → $21 | Maintains | Outperform | Get Alert |
| 01/24/2023 | TSVT | Buy Now | 2seventy bio | $4.64 | 503.45% | Morgan Stanley | Matthew Harrison | $29 → $28 | Maintains | Overweight | Get Alert |
FAQ
What is the target price for 2seventy bio (TSVT)?
The latest price target for 2seventy bio (NASDAQ: TSVT) was reported by Citigroup on April 8, 2024. The analyst firm set a price target for $12.00 expecting TSVT to rise to within 12 months (a possible 158.62% upside). 17 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for 2seventy bio (TSVT)?
The latest analyst rating for 2seventy bio (NASDAQ: TSVT) was provided by Citigroup, and 2seventy bio maintained their buy rating.
When was the last upgrade for 2seventy bio (TSVT)?
The last upgrade for 2seventy bio Inc happened on January 31, 2024 when Leerink Partners raised their price target to $18. Leerink Partners previously had a market perform for 2seventy bio Inc.
When was the last downgrade for 2seventy bio (TSVT)?
The last downgrade for 2seventy bio Inc happened on January 31, 2024 when TD Cowen changed their price target from N/A to N/A for 2seventy bio Inc.
When is the next analyst rating going to be posted or updated for 2seventy bio (TSVT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of 2seventy bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for 2seventy bio was filed on April 8, 2024 so you should expect the next rating to be made available sometime around April 8, 2025.
Is the Analyst Rating 2seventy bio (TSVT) correct?
While ratings are subjective and will change, the latest 2seventy bio (TSVT) rating was a maintained with a price target of $9.00 to $12.00. The current price 2seventy bio (TSVT) is trading at is $4.64, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.